SG10201503407WA - Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors - Google Patents

Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors

Info

Publication number
SG10201503407WA
SG10201503407WA SG10201503407WA SG10201503407WA SG10201503407WA SG 10201503407W A SG10201503407W A SG 10201503407WA SG 10201503407W A SG10201503407W A SG 10201503407WA SG 10201503407W A SG10201503407W A SG 10201503407WA SG 10201503407W A SG10201503407W A SG 10201503407WA
Authority
SG
Singapore
Prior art keywords
vegf
adjuvant
treatment
early stage
specific antagonists
Prior art date
Application number
SG10201503407WA
Other languages
English (en)
Inventor
Napoleone Ferrara
Nina Korsisaari
Robert D Mass
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG10201503407WA publication Critical patent/SG10201503407WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG10201503407WA 2006-12-19 2007-12-18 Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors SG10201503407WA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US87074106P 2006-12-19 2006-12-19
US87074506P 2006-12-19 2006-12-19
US87726706P 2006-12-27 2006-12-27
US91963807P 2007-03-22 2007-03-22
US95838407P 2007-07-05 2007-07-05
US98939707P 2007-11-20 2007-11-20

Publications (1)

Publication Number Publication Date
SG10201503407WA true SG10201503407WA (en) 2015-06-29

Family

ID=39323719

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201503407WA SG10201503407WA (en) 2006-12-19 2007-12-18 Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
SG2011080801A SG176448A1 (en) 2006-12-19 2007-12-18 Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2011080801A SG176448A1 (en) 2006-12-19 2007-12-18 Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors

Country Status (28)

Country Link
US (6) US20080248033A1 (fr)
EP (2) EP2101807B1 (fr)
JP (4) JP2010513566A (fr)
KR (5) KR20140148491A (fr)
CN (1) CN103143017A (fr)
AR (1) AR064458A1 (fr)
AU (1) AU2007333735A1 (fr)
BR (1) BRPI0720552A2 (fr)
CA (1) CA2671734A1 (fr)
CO (1) CO6210829A2 (fr)
CR (1) CR10940A (fr)
DK (1) DK2101807T3 (fr)
EC (1) ECSP099523A (fr)
ES (1) ES2582656T3 (fr)
HK (1) HK1133210A1 (fr)
HU (1) HUE029445T2 (fr)
IL (1) IL238913A0 (fr)
MA (1) MA31150B1 (fr)
MX (1) MX2009006779A (fr)
MY (1) MY183404A (fr)
NO (1) NO20092604L (fr)
NZ (1) NZ578472A (fr)
PL (1) PL2101807T3 (fr)
RU (1) RU2013129450A (fr)
SG (2) SG10201503407WA (fr)
SI (1) SI2101807T1 (fr)
TW (2) TW200831538A (fr)
WO (1) WO2008077077A2 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8349322B2 (en) 2008-06-25 2013-01-08 ESBATech, an Alcon Biomedical Research Unit, LLC Stable and soluble antibodies inhibiting VEGF
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
HUE024872T2 (en) * 2008-11-22 2016-02-29 Hoffmann La Roche Use of anti-vegf antibody in combination with chemotherapy to treat breast cancer
WO2010091234A2 (fr) * 2009-02-06 2010-08-12 The General Hospital Corporation Procédés de traitement de lésions vasculaires
KR101431318B1 (ko) 2009-04-02 2014-08-20 로슈 글리카트 아게 전장 항체 및 단일쇄 ｆａｂ 단편을 포함하는 다중특이성 항체
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
WO2010123891A1 (fr) * 2009-04-20 2010-10-28 Genentech, Inc. Thérapie adjuvante de cancer
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
AU2010296018B2 (en) 2009-09-16 2016-05-05 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
JP5965318B2 (ja) 2009-10-16 2016-08-03 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｄｌｌ４アンタゴニストおよび降圧剤の治療的併用およびそれらによる治療の方法
US9387211B2 (en) 2010-02-01 2016-07-12 Cedars-Sinai Medical Center Methods for treatment of Cushing'S disease and hypercortisolism using gefitinib
US20120308567A1 (en) * 2010-02-01 2012-12-06 Cedars-Sinai Medical Center Use of tyrosine kinase inhibitors for treatment of prolactinoma
US9427429B2 (en) 2010-03-01 2016-08-30 Tau Therapeutics Llc Cancer diagnosis and imaging
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
WO2012009705A1 (fr) 2010-07-15 2012-01-19 Zyngenia, Inc. Complexes liant ang-2 et leurs utilisations
BR112012033423A2 (pt) * 2010-07-19 2016-10-25 Hoffmann La Roche métodos para melhorar a eficácia do tratamento de um regime de quimioterapia e in vitro, usos de bevacizumab e de sondas específicas, kit e uso de um polipeptídeo
MX340558B (es) 2010-08-24 2016-07-14 F Hoffmann-La Roche Ag * Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
EP2655413B1 (fr) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Complexe polypeptide-polynucléotide et son utilisation dans l'administration d'une fraction effectrice ciblée
BR112013020338A2 (pt) 2011-02-28 2016-10-18 Hoffmann La Roche proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira
WO2012116926A1 (fr) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Protéines de liaison à un antigène
WO2012135624A1 (fr) * 2011-04-01 2012-10-04 The Trustees Of The University Of Pennsylvania Traitement du cancer du côlon au moyen d'inhibiteurs du complément
WO2012151574A1 (fr) 2011-05-05 2012-11-08 Duke University Procédés pour mettre au point un pronostic du cancer du pancréas et prédire la réponse à une thérapie contre le cancer
WO2012162561A2 (fr) 2011-05-24 2012-11-29 Zyngenia, Inc. Complexes plurispécifiques multivalents et monovalents, et leurs utilisations
EP2755674A4 (fr) * 2011-09-12 2015-04-08 Tau Therapeutics Llc Antagonistes des produits du groupe unigene hs.459642 pour inhiber la prolifération, le développement ou la différenciation des cellules souches comprenant des cellules souches cancéreuses
HRP20230078T1 (hr) 2011-09-23 2023-05-12 Mereo Biopharma 5, Inc. Sredstva za vezivanje vegf/dll4 i njihova uporaba
US20130142796A1 (en) * 2011-12-05 2013-06-06 Subhransu Ray Treatment for angiogenic disorders
BR112014019579A2 (pt) 2012-02-10 2019-10-15 Genentech, Inc Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
WO2014001324A1 (fr) 2012-06-27 2014-01-03 Hoffmann-La Roche Ag Méthode de sélection et de production d'entités de ciblage personnalisées fortement sélectives et multi-spécifiques renfermant au moins deux entités de liaison différentes et leurs utilisations
EP2867254B1 (fr) 2012-06-27 2017-10-25 F. Hoffmann-La Roche AG Procédé de fabrication de conjugués de régions fc comprenant au moins une portion capable de se lier de manière spécifique à une cible et utilisations desdits conjugués
AU2013288641B2 (en) 2012-07-13 2017-07-06 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
CA2889638A1 (fr) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methodes et surveillance d'un traitement par un antagoniste de dll4
EP2925887B1 (fr) 2012-12-03 2018-03-07 Koninklijke Philips N.V. Estimation du résultat de prédiction pour une chimiothérapie par un néo-adjuvant bévacizumab
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
US20160176962A1 (en) 2014-10-31 2016-06-23 Oncomed Pharmaceuticals, Inc. Combination Therapy For Treatment Of Disease
WO2016087416A1 (fr) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Anticorps multispécifiques
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
JP2019506602A (ja) * 2015-12-30 2019-03-07 ヴィジョンゲイト，インコーポレーテッド 異形成を自動的に検出しモニターし、化学予防を施行するためのシステム及び方法
WO2017201166A1 (fr) * 2016-05-17 2017-11-23 Duke University Méthodes de prédiction de la réaction d'un cancer à un agent de ciblage du vegf et méthodes de pronostic et de traitement du cancer
WO2019126329A1 (fr) * 2017-12-19 2019-06-27 Akouos Llc Administration d'anticorps thérapeutiques médiée par aav à l'oreille interne
US11026649B2 (en) * 2018-06-25 2021-06-08 Siemens Medical Solutions Usa, Inc. Method and system for determining tumor burden in medical images
US20220135651A1 (en) * 2019-02-18 2022-05-05 Agency For Science, Technology And Research A membrane-bound fit-1 decoy and uses thereof
CA3139162A1 (fr) * 2019-05-17 2020-11-26 Cancer Prevention Pharmaceuticals, Inc. Methodes de traitement de la polypose adenomateuse familiale
CN112773852A (zh) * 2021-03-16 2021-05-11 宁夏医科大学 一种对细胞有保护作用的中草药组合物的制备工艺
CN113512589B (zh) * 2021-07-14 2023-03-10 复旦大学附属中山医院 Prune1基因检测在多发性骨髓瘤患者预后中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JP2763958B2 (ja) 1990-06-11 1998-06-11 ネクスター ファーマスーティカルズ，インコーポレイテッド 核酸リガンド
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0546073B1 (fr) 1990-08-29 1997-09-10 GenPharm International, Inc. production et utilisation des animaux non humains transgeniques capable de produire des anticorps heterologues
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0564531B1 (fr) 1990-12-03 1998-03-25 Genentech, Inc. Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
DK1167384T3 (da) 1992-10-28 2007-04-10 Genentech Inc Vaskular endotheliel cellevækstfaktor antagonister
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU2582897A (en) 1996-03-15 1997-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
TR199902818T2 (xx) 1997-04-07 2000-05-22 Genentech, Inc. Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler.
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US20030114407A1 (en) 2001-12-06 2003-06-19 Monia Brett P. Antisense modulation of G protein-coupled receptor ETBR-LP-2 expression
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
NZ514918A (en) 1999-04-28 2003-11-28 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting VEGF
JP2001072587A (ja) * 1999-07-01 2001-03-21 Taisho Pharmaceut Co Ltd Ｖｅｇｆ受容体拮抗剤
DE60042021D1 (de) 1999-07-29 2009-05-28 Gilead Sciences Inc Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
RS20150135A1 (en) 2003-05-30 2015-08-31 Genentech Inc. TREATMENT WITH ANTI-VEGF ANTIBODIES
EP2093570A1 (fr) 2003-06-06 2009-08-26 Genentech, Inc. Modulation de l'interaction entre la chaîne HGF bêta et c-MET
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20050044853A1 (en) * 2003-09-02 2005-03-03 Kazutora Yoshino Ecology system
US7354580B2 (en) * 2004-06-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of administering and using VEGF inhibitors for the treatment of human cancer
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
KR101254815B1 (ko) * 2004-07-20 2013-09-03 제넨테크, 인크. 안지오포이에틴-유사 4 단백질의 저해제, 배합물, 그의용도

Also Published As

Publication number Publication date
EP2101807A2 (fr) 2009-09-23
JP2018052939A (ja) 2018-04-05
US20120148584A1 (en) 2012-06-14
CR10940A (es) 2009-08-13
AU2007333735A1 (en) 2008-06-26
ES2582656T3 (es) 2016-09-14
AR064458A1 (es) 2009-04-01
TW200831538A (en) 2008-08-01
EP3095455A1 (fr) 2016-11-23
US20180208647A1 (en) 2018-07-26
HUE029445T2 (en) 2017-02-28
MY183404A (en) 2021-02-18
AU2007333735A2 (en) 2009-11-05
MA31150B1 (fr) 2010-02-01
EP2101807B1 (fr) 2016-05-25
IL238913A0 (en) 2015-06-30
US20140178363A1 (en) 2014-06-26
WO2008077077A2 (fr) 2008-06-26
WO2008077077A3 (fr) 2008-08-14
JP2013189452A (ja) 2013-09-26
NZ578472A (en) 2012-06-29
KR20150097813A (ko) 2015-08-26
RU2013129450A (ru) 2015-01-10
CO6210829A2 (es) 2010-10-20
CN103143017A (zh) 2013-06-12
JP2010513566A (ja) 2010-04-30
TWI577695B (zh) 2017-04-11
US20110052576A1 (en) 2011-03-03
KR20140031996A (ko) 2014-03-13
HK1133210A1 (zh) 2010-03-19
TW201525003A (zh) 2015-07-01
KR20140148491A (ko) 2014-12-31
SG176448A1 (en) 2011-12-29
PL2101807T3 (pl) 2016-11-30
US20160108116A1 (en) 2016-04-21
US20080248033A1 (en) 2008-10-09
KR20130060309A (ko) 2013-06-07
KR20090097188A (ko) 2009-09-15
BRPI0720552A2 (pt) 2014-01-07
NO20092604L (no) 2009-09-18
SI2101807T1 (sl) 2016-08-31
MX2009006779A (es) 2009-08-27
ECSP099523A (es) 2009-09-29
JP2015110609A (ja) 2015-06-18
CA2671734A1 (fr) 2008-06-26
DK2101807T3 (en) 2016-08-29

Similar Documents

Publication Publication Date Title
IL238913A0 (en) Vegf-specific antagonists for adjuvant therapy and treatment of early-stage tumors
IL248204A0 (en) Combined treatment of tumors expressing 38cd
EP1985302A4 (fr) Médicament pour le traitement de tumeurs et son utilisation
GB0700560D0 (en) Device and method for the treatment of diseased tissue such as tumours
EP1814909A4 (fr) Utilisation de aimp2dx2 pour diagnostiquer et traiter un cancer
EP2211913A4 (fr) Administration systémique d'agents de chlorotoxine pour le diagnostic et le traitement de tumeurs
EP1994181A4 (fr) Identification et utilisation de novopeptides pour le traitement du cancer
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
EP2212440A4 (fr) Procédés et compositions destinés au diagnostic et au traitement de l'adénocarcinome de l' sophage
EP1971278A4 (fr) Dispositif de traitement abrasif superficiel de la peau
IL188430A0 (en) Treatment of tumors
IL179515A0 (en) Method of administering and using vegf inhibitors for the treatment of human cancer
IL193747A0 (en) New therapeutic combinations for the treatment of depression
EP2049139A4 (fr) Traitement de tumeurs exprimant ras
EP2046973A4 (fr) Procédés d'identification, d'évaluation, et de traitement de patients soumis à une thérapie anticancéreuse
GB0604471D0 (en) Device and method for the treatment of tumours
PT2056842E (pt) Galactosil-ceramidas modificadas para coloração e estimulação de células t assassinas naturais
PT2101731T (pt) Endoxifeno para utilização no tratamento de cancro
EP2029156A4 (fr) Polythérapie pour traiter le cancer
ZA200709542B (en) Combination therapy in the treatment of cancer
EP1737475A4 (fr) Therapie a base d'herbes medicinales pour le traitement de l'asthme
IL226363A0 (en) Compounds and methods for treating cancer
EP1797430A4 (fr) Methodes et compositions de diagnostic et de traitement du cancer
ZA200904571B (en) VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors